Regeneron Pharmaceuticals, Inc. (REGN) Discusses C5 Complement Development Program Focusing on Cemdisiran and Pozelimab for Complement-Mediated Diseases Transcript
Summary
Regeneron Pharmaceuticals, Inc. (REGN) Discusses C5 Complement Development Program Focusing on Cemdisiran and Pozelimab for Complement-Mediated Diseases...
Description
Regeneron Pharmaceuticals, Inc. (REGN) Discusses C5 Complement Development Program Focusing on Cemdisiran and Pozelimab for Complement-Mediated Diseases...
Original reporting
AFBytes is a read-only aggregator. Use the original source for full context and complete reporting.
Open original source